Genotype specific peripheral lipid profile changes with hepatitis C therapy

Table 1 Baseline demographics n (%)

	All	Genotype 1	Genotype 2	Genotype 3	P value
Number of patients	321 (100)	232 (72.3)	58 (18.1)	31 (9.7)
Age (yr)	57.7 ± 10.3	58.9 ± 9.5	55.5 ± 12.1	54.6 ± 10.8	0.009
Gender (male)	221 (68.8)	160 (59.4)	41 (61.2)	20 (64.5)	0.845
Ethnicity
Caucasian	229 (71.3)	171 (73.7)	40 (70.0)	18 (58.1)	0.018
African American	19 (5.9)	18 (7.8)	1 (1.7)	0 (0.0)
Hispanic	55 (17.1)	32 (13.8)	13 (22.4)	10 (32.3)
Asian	16 (5.0)	9 (3.9)	4 (6.9)	3 (9.7)
Other	2 (0.6)	2 (0.9)	0 (0.0)	0 (0.0)
Diabetes	79 (24.6)	59 (25.4)	14 (24.2)	6 (19.4)	0.593
Hypertension	132 (41.1)	105 (45.3)	22 (37.9)	5 (16.1)	0.086
Hyperlipidemia	59 (18.4)	44 (19.0)	12 (20.7)	3 (9.7)	0.453
Cirrhotic	150 (46.7)	103 (44.4)	33 (56.9)	14 (45.2)	< 0.001
Treatment
IFN + SOF + RBV		25 (10.8)	0 (0.0)	0 (0.0)
SOF + RBV		57 (24.6)	58 (100)	31 (100)
SOF + SMV		42 (19.0)	0 (0.0)	0 (0.0)
SOF + LDV		140 (60.3)	0 (0.0)	0 (0.0)

IFN: Pegylated interferon; SOF: Sofosbuvir; RBV: Ribavirin; SMV: Simeprevir; LDV: Ledipasvir.